Global Pamiparib Market Strategic Research Report

Scope of the Report

The global Pamiparib market size is predicted to grow from US$ 117 million in 2025 to US$ 416 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.

In 2025, global Pamiparib production reached approximately 350,000 units.Pamiparib is an oral small-molecule targeted therapy that belongs to the class of Poly(ADP-ribose) polymerase (PARP) inhibitors. It is mainly used to treat tumors with homologous recombination repair deficiencies, such as those with BRCA mutation, including ovarian cancer and breast cancer. It works by inhibiting the activity of PARP enzymes, thereby blocking the repair of DNA damage in cancer cells and ultimately inducing tumor cell death. Pamiparib also has good penetration across the blood–brain barrier, showing potential therapeutic value in tumors with central nervous system metastases.

Pamiparib, as one of the domestically developed innovative PARP inhibitors, is positioned within the rapidly growing targeted anti-cancer drug market. Driven by the increasing adoption of BRCA mutation testing, the advancement of precision medicine, and the rising incidence of cancer, the overall PARP inhibitor market continues to expand. In the Chinese market, Pamiparib holds certain competitive advantages due to its local R&D background, particularly in pricing, reimbursement access, and clinical availability. In addition, its strong ability to penetrate the blood–brain barrier provides a point of differentiation. Currently, the drug is still in the stage of market introduction and volume expansion. Future growth will mainly depend on the expansion of indications (such as breast cancer and ovarian cancer), combination therapy strategies, and international market development. However, it also faces challenges such as intensified competition from other PARP inhibitors and pressure from healthcare cost control policies.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pamiparib market?

What factors are driving Pamiparib market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pamiparib market opportunities vary by end market size?

How does Pamiparib break out by Type, by Application?

This report presents a comprehensive overview of the global Pamiparib market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 20 mg/vial
• 50 mg/vial

Segment by Combined Medication

• Pamiparib + Tislelizumab
• Pamiparib + Anlotinib

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Advanced Ovarian Cancer
• Fallopian Tube Cancer
• Primary Peritoneal Cancer
• Primary Peritoneal Carcinoma (PPC)
• Endometrial Cancer
• Prostate Cancer
• Pancreatic Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pamiparib market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Advanced Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact